Get to know our clinical trials
Clinical trial with E7386 in combination with Pembrolizumab in previously treated patients with specific solid tumors.
PRIMARY OBJECTIVE: PHASE IB PART: - TO EVALUATE THE SAFETY AND TOLERABILITY OF E7386 IN COMBINATION WITH PEMBROLIZUMAB IN PREVIOUSLY TREATED PATIENTS WITH SPECIFIC SOLID TUMORS - TO DETERMINE THE RECOMMENDED DOSE FOR PHASE 2 (DRF2) OF E7386 IN COMBINATION WITH PEMBROLIZUMAB PART PHASE 2: - TO EVALUATE THE OBJECTIVE RESPONSE RATE (ORR) OF E7386 IN COMBINATION WITH PEMBROLIZUMAB IN PREVIOUSLY TREATED PATIENTS WITH SPECIFIC SOLID TUMORS (MELANOMA, RCC, HCC).
Technical Summary
- OPEN-LABEL, MULTICENTER, PHASE 1B/2 STUDY WITH E7386 IN COMBINATION WITH PEMBROLIZUMAB IN PREVIOUSLY TREATED PATIENTS WITH SPECIFIC SOLID TUMORS. IMMUNOTHERAPY.
- Code EudraCT: 2021-001568-10
- Protocol number: E7386-G000-201
- Promoter: Eisai Inc.
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.